Our study was carried out on forty polytrauma patients admitted to intensive care units, between July 2012 and February 2013, twenty patients receiving L-alanyl L-glutamine dipeptide (Dipeptiven® Fresenius Kabi) and twenty patients, age matched not receiving the drug serving as the control group. The patients and controls were subjected to full medical history, complete medical examination on ICU admission and laboratory investigations including complete blood picture, C-reactive protein, serum albumin level and random blood sugar on day 1 and day 8. Also, ICU stay and hospital stay were recorded to detect the difference between the 2 studied groups. The results of our study were statistically analyzed and we found that the patients receiving L-alanyl L-glutamine dipeptide showed reduction in the incidence of infectious complications of polytrauma ICU patients, improved glucose metabolism and reduction in the period of ICU and hospital stay but further investigations are required on larger scale of patients.